NyxoahNYXH
About: Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Employees: 184
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
39% more capital invested
Capital invested by funds: $39.1M [Q3] → $54.4M (+$15.3M) [Q4]
10% more funds holding
Funds holding: 20 [Q3] → 22 (+2) [Q4]
7.77% more ownership
Funds ownership: 11.95% [Q3] → 19.72% (+7.77%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Stifel Jonathan Block 11% 1-year accuracy 2 / 19 met price target | 128%upside $14 | Buy Maintained | 21 Apr 2025 |
HC Wainwright & Co. Edward White 22% 1-year accuracy 32 / 148 met price target | 144%upside $15 | Buy Reiterated | 8 Apr 2025 |
Financial journalist opinion
Based on 39 articles about NYXH published over the past 30 days
